Trial · NCT04334460
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Recovery | Course of study; 28 days | To evaluate time to recovery as defined by no longer requiring oxygen support or hospital discharge, whichever occurs first. |
| Primary | Change in Oxygenation | 10 days | To evaluate change in oxygenation in hospitalized adults with COVID-19 treated with BLD-2660. Measured by change from baseline to Day 10 or hospital discharge, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) |
| Secondary | Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs) | Course of study; 28 days | To evaluate the safety and tolerability of BLD-2660 in the same population. Measured by incidence of TEAEs and serious adverse events (SAEs) |
| Other | Time to Discharge Readiness | Course of study; 28 days | Measured by time to discharge readiness |
| Other | Proportion of Subjects Discharged During Study | Course of study; 28 days | Measured by proportion of subjects ready to be discharged from the hospital during the 28-day study period following enrollment. |
| Other | Time to Resolution of Fever | Course of study; 28 days | Measured by time to resolution of fever below entry criteria for 24 hours in subjects with fever at baseline |
| Other | Duration of Remdesivir Use | Course of study; 28 days | Measured by duration (in days) of remdesivir use in subjects starting remdesivir within 24 hours of first dose of BLD-2660 |
| Other | Change in Clinical Status | Course of study; 28 days | Measured by change from baseline to Days 10, 14, 21 and 28 in clinical status outcome using a 6-point ordinal scale |
| Other | Percentage of Subjects in Each Category of the 6-point Ordinal Scale | Course of study; 28 days | Measured by percentage of subjects reporting each 6-point ordinal scale of the clinical status outcome assessment. |
| Other | Change in IL-6 | Course of study; 28 days | Measured by change from baseline to Days 10, 14, 21 and 28 in IL-6 in ng/mL measured by analytical assay |
| Other | Change in D-dimer | Course of study; 28 days | Measured by change from baseline to Days 10, 14, 21 and 28 in D-dimer in ng/mL measured by analytical assay |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04334460/registered